Nathalie Goutté1, Philippe Sogni2, Noelle Bendersky3, Jean Claude Barbare4, Bruno Falissard5, Olivier Farges6. 1. Pôle des Maladies Digestives U773 - Université Paris Nord Val de Seine, Hôpital Beaujon, Assistance Publique - Hôpitaux de Paris, Clichy, France. 2. Université Paris-Descartes, INSERM U-1223, Institut Pasteur and Département d'Hépatologie, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France. 3. Service Département Informatique Médicale, Hôpital Beaujon, Assistance Publique - Hôpitaux de Paris, Clichy, France. 4. Centre Hospitalo-universitaire d'Amiens - Coordination du Réseau des Investigateurs pour le Carcinome Hépatocellulaire, France. 5. U669 - Université Paris Sud, Hôpital Cochin - Maison des adolescents, Paris, France. 6. Pôle des Maladies Digestives U773 - Université Paris Nord Val de Seine, Hôpital Beaujon, Assistance Publique - Hôpitaux de Paris, Clichy, France. Electronic address: olivier.farges@aphp.fr.
Abstract
BACKGROUND & AIMS: Information on the incidence, management, and prognosis of hepatocellular carcinoma (HCC) is derived from population samples, regional data, or registries. Comprehensive national evaluations within a given country are lacking. This study aimed to investigate regional variations in HCC care within France. METHODS: This observational study analysed data from French administrative databases for more than 30,000 patients with HCC diagnosed between 2009 and 2012, and followed-up until 2013. The incidence of HCC, access to surgery, and survival, at both the national level and two geographical levels (the 21 French regions and 95 French departments into which France is divided administratively), were determined. The influence on outcome of the structure of the hospital where HCC was first managed was assessed. RESULTS: At the national level, the median survival was 9.4months and only 22.8% of patients had curative treatment. There were marked variations between regions and departments in incidence, access to curative treatment (range 1.3-28.8% and 8.1-32.3% respectively), and in median survival (range 5.7-12.1 and 4.3-16.5months respectively). The administrative type and annual HCC-caseload of the hospital where patients were first admitted also had an independent influence on treatment and survival. CONCLUSION: Despite full insurance coverage for all citizens, national measures to reduce inequities in the management of cancer patients, standardised recommendations for HCC surveillance and management, the percentage of patients undergoing curative treatment and their survival may vary four-fold depending on their postcode. The hospital in which patients are first managed has a clear influence on accessibility to both good care and survival. LAY SUMMARY: Population-based studies have highlighted large and sometimes unexpected differences between countries in the survival of patients with malignancy. As these differences are considered to indicate the overall effectiveness of health systems, in addition to the incidence of the cancer or quality of registration, variations within a given country should be minimal. However, similar to between countries differences, this study shows differences within the same country in the incidence, curative treatment rate, and survival of patients with HCC. Evidence that access to care and survival varies within a country can strengthen the impetus for government and clinicians to address these disparities.
BACKGROUND & AIMS: Information on the incidence, management, and prognosis of hepatocellular carcinoma (HCC) is derived from population samples, regional data, or registries. Comprehensive national evaluations within a given country are lacking. This study aimed to investigate regional variations in HCC care within France. METHODS: This observational study analysed data from French administrative databases for more than 30,000 patients with HCC diagnosed between 2009 and 2012, and followed-up until 2013. The incidence of HCC, access to surgery, and survival, at both the national level and two geographical levels (the 21 French regions and 95 French departments into which France is divided administratively), were determined. The influence on outcome of the structure of the hospital where HCC was first managed was assessed. RESULTS: At the national level, the median survival was 9.4months and only 22.8% of patients had curative treatment. There were marked variations between regions and departments in incidence, access to curative treatment (range 1.3-28.8% and 8.1-32.3% respectively), and in median survival (range 5.7-12.1 and 4.3-16.5months respectively). The administrative type and annual HCC-caseload of the hospital where patients were first admitted also had an independent influence on treatment and survival. CONCLUSION: Despite full insurance coverage for all citizens, national measures to reduce inequities in the management of cancerpatients, standardised recommendations for HCC surveillance and management, the percentage of patients undergoing curative treatment and their survival may vary four-fold depending on their postcode. The hospital in which patients are first managed has a clear influence on accessibility to both good care and survival. LAY SUMMARY: Population-based studies have highlighted large and sometimes unexpected differences between countries in the survival of patients with malignancy. As these differences are considered to indicate the overall effectiveness of health systems, in addition to the incidence of the cancer or quality of registration, variations within a given country should be minimal. However, similar to between countries differences, this study shows differences within the same country in the incidence, curative treatment rate, and survival of patients with HCC. Evidence that access to care and survival varies within a country can strengthen the impetus for government and clinicians to address these disparities.
Authors: Daiana Bezzini; L Policardo; F Profili; G Meucci; M Ulivelli; S Bartalini; P Francesconi; M A Battaglia Journal: Neurol Sci Date: 2018-08-08 Impact factor: 3.307
Authors: Michael C Wallace; Kenny Sek; Roslyn J Francis; Shaun Samuelson; John Ferguson; Jonathan Tibballs; Ali Asad; David B Preen; Gerry MacQuillan; George Garas; Leon A Adams; Gary P Jeffrey Journal: Dig Dis Sci Date: 2019-08-22 Impact factor: 3.199
Authors: Nina Weiler; Andreas Schlotmann; Andreas Anton Schnitzbauer; Stefan Zeuzem; Martin-Walter Welker Journal: Dtsch Arztebl Int Date: 2020-01-24 Impact factor: 5.594
Authors: Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet Journal: CA Cancer J Clin Date: 2017-07-06 Impact factor: 508.702